Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F24%3AA25039NA" target="_blank" >RIV/61988987:17110/24:A25039NA - isvavai.cz</a>
Result on the web
<a href="https://ashpublications.org/bloodadvances/article/8/15/3875/516313/Targeting-CD38-with-isatuximab-and-a-novel-CD38" target="_blank" >https://ashpublications.org/bloodadvances/article/8/15/3875/516313/Targeting-CD38-with-isatuximab-and-a-novel-CD38</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/bloodadvances.2024013212" target="_blank" >10.1182/bloodadvances.2024013212</a>

Result language
angličtina
Original language name
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia
Original language description
This study explores the potential of targeting CD38 in older patients with acute myeloid leukemia (AML) using isatuximab and a novel trispecific CD38/CD3×CD28 T-cell engager (CD38-TCE). CD38 expression was analyzed in AML patients ineligible for intensive chemotherapy, revealing widespread but variable CD38 levels. Preclinical studies demonstrated that isatuximab and CD38-TCE effectively induced tumor cell lysis through immune cell activation, with CD38-TCE showing a stronger effect independent of CD38 density. These findings suggest that CD38-targeting immunotherapies could be promising treatment options for AML, particularly in older patients. Further in vivo studies are warranted.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)